Tag Archives: Hip

FDA Advisory Committee Briefing hits Bayer’s Xarelto® badly.

By Xavier Tello One of the most desired markets of the pharmaceutical business has been the clotting-prevention. Ever since the first use of systemic heparin and the late surging of the low molecular weight heparins (LMWH) such as Lovenox® (enoxaparin), … Continue reading

Posted in Alta Dirección, Mercadotecnia, Salud, Ventas | Tagged , , , , , , , , , , , , , , , , , , , | Leave a comment